FDA panel backs anemia drugs for kidney disease

Oct 18, 2010

(AP) -- Federal health advisers say patients with failing kidneys should continue taking a group of widely used anemia drugs, despite a recent study showing they can increase the risk of stroke.

A panel of experts voted 15-1 to maintain the drugs' approval for patients with chronic who are not yet sick enough to receive dialysis. The FDA is not required to follow the group's advice, though it often does.

The panel is now scheduled to discuss altering recommended doses of the drugs to increase their safety.

The FDA is reviewing the three blood-boosting medications from Amgen Inc. after a study published last year that showed kidney disease patients taking them were twice as likely to experience compared with those taking a dummy treatment.

Explore further: Mirabegron for overactive bladder: Added benefit not proven

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Study finds stroke risk from anemia drug Aranesp

Oct 31, 2009

(AP) -- A new study raises fresh safety concerns about widely used anemia medicines, finding that the drug Aranesp nearly doubled the risk of stroke in people with diabetes and chronic kidney problems who are not yet sick ...

FDA questions safety of Glaxo kidney cancer drug

Oct 01, 2009

(AP) -- Federal regulators said Thursday an experimental kidney cancer drug from GlaxoSmithKline may cause liver problems, potentially outweighing its ability to slow the disease.

Abbott withdraws diet pill in US, Canada

Oct 08, 2010

(AP) -- Abbott Laboratories said Friday it will withdraw its diet pill Meridia in the U.S. and Canada, almost a year after studies showed the drug increases the risk of heart attack and stroke in patients with a history ...

FDA confirms benefits of Crestor in more patients

Dec 11, 2009

(AP) -- Federal scientists say AstraZeneca's cholesterol pill Crestor lowers the risk of heart attack, death and stroke in patients without a history of heart disease, though some safety concerns remain.

Recommended for you

Mirabegron for overactive bladder: Added benefit not proven

12 minutes ago

Mirabegron (trade name: Betmiga) has been approved since December 2012 for the treatment of adults with overactive bladder. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products ...

Novartis Japan admits concealing drug side effects

Sep 01, 2014

The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities.

Most US babies get their vaccines, CDC says

Aug 28, 2014

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

User comments : 0